9/27/2011

A European panel of advisers supported Bayer HealthCare's anticoagulant Xarelto to prevent systemic embolism and stroke in patients with nonvalvular atrial fibrillation. Xarelto was also recommended for treatment of deep vein thrombosis.

Full Story:
InPharm.com

Related Summaries